证券代码：000566 证券简称：海南海药 公告编号：2023-054 海南海药股份有限公司 关于子公司获得政府补助的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、获得补助的基本情况 根据海口市人民政府制定的《海口市加快工业发展若干规定（2021年修订）》 的相关规定，海南海药股份有限公司（以下简称"公司"）全资子公司海口市制 药厂有限公司(以下简称"海口市制药厂")近日收到海口市科学技术工业信息化 局拨付的2021年度运输费补贴共计117.37万元，占公司最近一个会计年度经审计 的归属于上市公司股东净利润的11.16%，具体情况如下: | 获得补 | 提供补助 | 获得补助的 | 补助 | | | 是否与公司 | 是否具 | | --- | --- | --- | --- | --- | --- | --- | --- | | 助的主 | 的主体 | 原因或项目 | 形式 | 金额 | 补助依据 | 日常经营活 | 有可持 | | 体 | | | | | | 动相关 | 续性 | | | 海口市科 | | 现金 | | 《海口市加快工 | | | ...

Group 1: Financial Performance - In 2022, the company achieved revenue of CNY 1.779 billion, with a net profit of CNY 10.5157 million, marking a turnaround from previous losses [2][5][7]. - The operating cash flow for 2022 was CNY 142 million, an increase of 31.37% year-on-year, indicating significant improvement in cash flow [3]. - The company disposed of non-core assets, recovering CNY 225 million, which contributed to enhancing capital operation efficiency [2]. Group 2: Business Strategy and Development - The company focuses on core pharmaceutical operations, optimizing product structure, and enhancing sales systems to address development constraints [2]. - It has established partnerships with domestic and international pharmaceutical companies, engaging in CMO/CDMO and CRO services, which support new drug development and production [1][2]. - The company plans to expand its product and industry structure, emphasizing the development of traditional Chinese medicine and exploring opportunities in the biopharmaceutical sector [2][3]. Group 3: Market Expansion and Export Growth - In 2022, the company's international export revenue reached CNY 102 million, a year-on-year increase of 37.18% [3][6]. - The company is actively exploring new markets and channels, leveraging the opportunities presented by the Hainan Free Trade Port [3]. Group 4: Research and Development - The R&D investment for 2022 was CNY 142 million, with 10 formulation products and 3 raw material products passing the consistency evaluation for generic drugs [4]. - The company aims to enhance its R&D capabilities, focusing on areas such as anti-infection, oncology, and gastrointestinal treatments [4]. Group 5: Challenges and Risk Management - The company faced challenges due to national drug procurement policies, which led to a decline in sales prices for some products [6]. - It has implemented strict internal controls and risk management measures to mitigate potential corruption risks and ensure compliance [5][7].

证券代码：000566 证券简称：海南海药 公告编号：2023-041 海南海药股份有限公司 董 事 会 二〇二三年五月二十日 海南海药股份有限公司关于参加 2022 年度海南辖区上市公司业绩说明会的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "海南辖区投资者网上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南海药股份有限公司（以下简称"公司"）主要高管人员将参加本 次活动，通过网络在线交流形式，就公司 2022 年年报披露、财务数据、公司治 理、内部控制、发展战略、经营状况、现金分红、重大事项、可持续发展等投资 者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者 踊跃参与。 特此公告。 ...

海南海药股份有限公司 2023 年第一季度报告 证券代码：000566 证券简称：海南海药 公告编号：2023-033 海南海药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 海南海药股份有限公司 2023 年第一季度报告 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 495, 029, 847. 71 | 553, 628, 983, 97 | | -10.58% | | 归属于上市公司 ...

Financial Performance - The company reported a total revenue of RMB 142.5 million for the year 2022, marking a year-on-year increase of 10%[18]. - The net profit attributable to shareholders was RMB 30 million, representing a growth of 15% compared to the previous year[18]. - The company's operating revenue for 2022 was ¥1,779,052,193.18, a decrease of 13.60% compared to ¥2,059,062,761.85 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥10,515,675.29, a significant recovery from a loss of ¥1,555,415,451.91 in 2021[6]. - The net cash flow from operating activities increased by 31.37% to ¥142,170,662.10 in 2022, compared to ¥108,223,441.12 in 2021[6]. - The company reported a significant increase in the sales of its gastrointestinal series products, which are used for treating acute gastroenteritis and food stagnation[49]. - The company achieved a significant reduction in losses, decreasing by 1.6 billion RMB year-on-year, and successfully met its annual goal of turning losses into profits[40]. - The company reported a total revenue of CNY 1.5 billion for the fiscal year 2022, representing a year-over-year increase of 12%[168]. - The net profit of the company for the year 2022 was reported at 2,945,580,000 CNY, reflecting a growth of 3.67% compared to the previous year[125]. Research and Development - The company plans to invest RMB 50 million in research and development for new products and technologies in 2023[18]. - The company invested 142 million RMB in R&D, with 10 formulation products and 20 specifications passing the consistency evaluation for generic drugs[41]. - The company is committed to innovation in the biopharmaceutical sector, with a focus on high-quality and high-innovation development[39]. - The company is focusing on optimizing its product structure and improving operational efficiency through asset disposal, recovering 225 million RMB from non-core assets[40]. - The company is actively working on over ten raw material products to expand its market presence and improve product quality[80]. - R&D personnel decreased by 22.84% from 162 in 2021 to 125 in 2022, with the proportion of R&D personnel in total employees dropping from 6.31% to 5.18%[81]. - The company is enhancing its incentive mechanisms and talent development to boost operational vitality, including a special incentive plan for R&D to accelerate new drug development[141]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 25% increase in market share by 2025[18]. - Future guidance estimates a revenue growth of 12% for 2023, driven by new product launches and market expansion efforts[18]. - The company is actively expanding into new markets, including e-commerce platforms and international markets, to drive growth[42]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of CNY 300 million allocated for this purpose[168]. - A strategic partnership with a leading pharmaceutical firm is expected to enhance distribution channels and increase market penetration[168]. - The company plans to continue clinical research on its anti-fibrosis drug, aiming to expand its chronic disease drug pipeline[80]. Financial Management and Investments - The company has received strong support from the Xinxing Jihua Group, which has enhanced investor confidence and reduced financing costs by 12.05% year-on-year[43]. - The company reported an investment income of ¥254,986,630.04, a significant increase of 785.16% compared to ¥28,806,715.68 from the previous year, due to gains from equity disposal[60]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 8% in the upcoming fiscal year[168]. - The company is focused on optimizing its financing structure and reducing interest-bearing debt to lower financing costs[135]. Compliance and Risk Management - The management emphasized the importance of maintaining compliance with GMP certification standards in all production processes[18]. - The company has identified potential risks in supply chain disruptions and is implementing measures to mitigate these risks[18]. - The company has maintained compliance with relevant laws and regulations throughout the reporting period[180]. - The company has focused on risk management, conducting quarterly risk assessments to address financial, market, and litigation risks[192]. Corporate Governance and Management - The company has a diverse management team, with key positions held by individuals aged between 33 and 66 years[153]. - The company has seen a significant turnover in its board and management, with multiple appointments and resignations occurring in 2022[155]. - The company’s independent directors include Wei Yu Lin and Zhang Qiang, both of whom have been in their positions since 2020[153]. - The company has improved its information disclosure quality and compliance management systems, ensuring transparency and protecting investor interests[141]. - The company has a structured remuneration decision-making process in place, ensuring transparency and accountability[173]. Employee and Operational Insights - The total number of employees at the end of the reporting period is 2,247, including 146 at the parent company and 2,101 at major subsidiaries[184]. - The company has established a three-level matrix training management system to enhance employee skills and promote organizational development[187]. - The company has implemented a performance management system linked to employee compensation, ensuring fairness and transparency[186]. - The company has not proposed any cash dividend distribution plan for the reporting period, despite having positive distributable profits[190].

Financial Performance - The company's revenue for Q3 2022 was ¥409,087,812.91, a decrease of 12.84% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥48,444,591.86, representing an increase in loss of 59.64% year-on-year[5]. - The company's basic earnings per share were -¥0.0374, a decrease of 59.57% year-on-year[5]. - The company recorded a loss from investment activities of ¥31,288,169.22, a significant increase compared to the previous year[8]. - Total operating revenue for the period was CNY 1,474,222,452.43, a decrease of 1.8% compared to CNY 1,499,550,598.88 in the previous period[26]. - Net profit for the period was a loss of CNY 49,809,751.72, compared to a loss of CNY 523,444,853.50 in the previous period, showing an improvement[27]. - The total comprehensive loss for the period was CNY 43,875,662.85, compared to a loss of CNY 524,201,221.85 in the previous period[28]. - Basic and diluted earnings per share were both CNY -0.0520, an improvement from CNY -0.3832 in the previous period[28]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥122,311,458.09, an increase of 256.97% compared to the same period last year[9]. - Cash and cash equivalents decreased by ¥321,629,385.65, a decline of 75.14% due to repayments of financing lease obligations[9]. - The cash and cash equivalents at the end of Q3 2022 were 226,879,517.28 CNY, up from 198,902,158.23 CNY at the end of Q3 2021, reflecting an increase of about 14%[29]. - The net cash flow from investment activities was 176,280,287.72 CNY in Q3 2022, compared to 374,179,447.67 CNY in Q3 2021, indicating a decrease of approximately 53%[29]. - The total cash inflow from financing activities was 3,670,756,806.67 CNY in Q3 2022, slightly down from 3,788,789,496.30 CNY in Q3 2021, representing a decrease of about 3.1%[29]. - The net cash flow from financing activities was -621,266,281.76 CNY in Q3 2022, compared to -591,585,653.87 CNY in Q3 2021, showing a worsening of approximately 5%[29]. - The cash flow from operating activities was not detailed in the provided content, indicating a focus on investment and financing activities[29]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,718,856,718.05, a decrease of 7.70% from the end of the previous year[5]. - The company's long-term equity investments decreased from CNY 502.61 million to CNY 463.48 million, a decline of approximately 7.8%[22]. - The company's total liabilities decreased from CNY 5.98 billion to CNY 5.40 billion, reflecting a reduction of about 9.7%[24]. - The company's current liabilities increased to approximately CNY 4.24 billion from CNY 4.68 billion at the beginning of the year, indicating a decrease of about 9.4%[24]. - The company reported a total of CNY 1.71 billion in fixed assets as of September 30, 2022, down from CNY 1.80 billion at the beginning of the year, representing a decrease of about 4.9%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 54,789[11]. - Hainan Huatong Industrial Co., Ltd. holds 22.89% of shares, totaling 296,989,889 shares, with 148,494,944 shares pledged[11]. - Shenzhen Nanfang Tongzheng Investment Co., Ltd. holds 10.56% of shares, totaling 136,966,587 shares, with 134,446,169 shares frozen[11]. - Yunnan International Trust Co., Ltd. holds 8.26% of shares, totaling 107,216,412 shares[11]. Debt and Repayment - The company has received a total of RMB 85 million from Sino Biological for debt repayment, with a repayment plan in place[13]. - The company has a debt repayment agreement requiring a total of RMB 23,045 million to be returned over three years[17]. - The repayment plan for the real estate project includes a minimum payment of RMB 12 million by December 31, 2021[16]. - The company signed a debt settlement agreement with Hainan Haiyao Real Estate, where 101 residential units will be used to settle the outstanding debt, valued at CNY 12,000 per square meter[18]. - The company has received CNY 18 million from Hainan Haiyao Real Estate, with a remaining debt of CNY 132 million as of December 31, 2021[18]. Operational Efficiency - Management expenses decreased by 38.88% to ¥128,277,928.54, attributed to cost-cutting measures[8]. - Total operating costs decreased to CNY 1,543,166,313.93 from CNY 1,769,241,502.99, representing a reduction of approximately 12.8%[26]. - The company recorded a decrease in sales expenses to CNY 369,506,809.06 from CNY 459,205,276.88, a reduction of approximately 19.5%[26]. - Research and development expenses decreased to CNY 41,827,877.77 from CNY 51,035,419.48, a decline of about 18.0%[26]. Legal and Compliance - The report for Q3 2022 was not audited, which may affect the reliability of the financial data presented[30]. - The company is actively responding to a legal dispute regarding the future acquisition of fund shares valued at CNY 193.34 million, with a premium calculated at an annual interest rate of 7.2%[19]. Investment Activities - The company achieved a cash inflow from investment activities of CNY 388,427,831.55, down from CNY 810,171,875.99 in the previous period[28]. - The total cash outflow from investment activities was 212,147,543.83 CNY in Q3 2022, down from 435,992,428.32 CNY in Q3 2021, indicating a decrease of approximately 51%[29]. - The company completed the transfer of 43% equity in Shanghai Lishengte Medical Technology Co., Ltd. for CNY 238.22 million, which will no longer be included in the consolidated financial statements[21].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,065,134,639.52, representing a 3.39% increase compared to ¥1,030,173,231.12 in the same period last year[22]. - The net loss attributable to shareholders was ¥18,989,077.33, a significant improvement of 94.96% from a loss of ¥377,129,265.61 in the previous year[22]. - The net cash flow from operating activities increased by 206.45% to ¥65,420,601.39, compared to ¥21,348,171.77 in the same period last year[22]. - The basic earnings per share improved to -¥0.0146, a 94.98% increase from -¥0.2907 in the previous year[22]. - The company's total revenue for the reporting period was ¥1,065,134,639.52, representing a year-on-year increase of 3.39% compared to ¥1,030,173,231.12 in the previous year[44]. - The operating costs decreased by 1.06% to ¥634,187,023.47 from ¥640,988,666.03, indicating effective cost management[44]. - The gross profit margin for the pharmaceutical segment was 41.84%, with a slight decrease of 1.76% compared to the previous year[47]. - Revenue from the pharmaceutical sector reached ¥934,977,828.85, accounting for 87.78% of total revenue, with a year-on-year growth of 4.01%[46]. - The company reported a significant increase in foreign revenue by 288.09%, reaching ¥68,541,322.84, compared to ¥17,661,147.90 in the previous year[46]. Asset Management - Total assets decreased by 6.94% to ¥7,782,713,026.73 from ¥8,362,720,404.64 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 0.76% to ¥2,132,803,467.33 from ¥2,149,227,286.82 at the end of the previous year[22]. - Cash and cash equivalents decreased to ¥293,234,735, accounting for 3.77% of total assets, down by 5.21% from the previous year[51]. - Accounts receivable increased to ¥595,253,389, representing 7.65% of total assets, up by 1.88% from the previous year[51]. - Inventory increased to ¥317,061,178, accounting for 4.07% of total assets, up by 0.96% from the previous year[51]. - Short-term borrowings rose to ¥1,834,539,680, representing 23.57% of total liabilities, an increase of 5.70% from the previous year[52]. - Long-term borrowings increased to ¥919,658,200, accounting for 11.82% of total liabilities, up by 3.61% from the previous year[52]. Research and Development - The company is advancing two major national new drug projects, with over 30 clinical centers initiated for the new drug targeting liver fibrosis[31]. - The company has completed the registration application for the generic drug Desloratadine oral solution and is progressing with seven consistency evaluation projects[31]. - The company has a diverse R&D strategy focusing on chemical drugs, biological drugs, traditional Chinese medicine, and medical devices, with a strong emphasis on independent innovation[38]. - Research and development investment slightly increased by 0.10% to ¥71,063,970.91, maintaining focus on innovation[44]. - The company is focusing on the development of new products, including a next-generation cochlear implant chip, which has successfully completed product registration submission[31]. - The company emphasizes increasing R&D investment and accelerating new product launches to adapt to regulatory changes and enhance core competitiveness[85]. Market Strategy - The company is enhancing its marketing network and adjusting sales channels to improve revenue structure and increase sales autonomy[32]. - The company has initiated a strategy to strengthen its core business while diversifying into high-value generics and specialty drugs[31]. - The company is actively developing the traditional Chinese medicine sector, with over 580 varieties planned for production and more than 100 currently in operation[36]. - The company is focusing on expanding its market presence in the traditional Chinese medicine sector, which is still in the cultivation phase[69]. - The company plans to enhance its market expansion strategies and product development in the upcoming quarters to improve overall financial performance[181]. - The company plans to expand its market presence by launching two new products in the next quarter, targeting a 10% increase in market share[194]. Environmental Responsibility - The company adheres to strict safety and environmental standards, enhancing pollution control measures to ensure compliance with national regulations[86]. - The wastewater treatment facility has a capacity of 400m³/d, ensuring that treated water meets the Class III discharge standard before entering the Sujia wastewater treatment plant[97]. - The company has implemented four sets of process waste gas treatment facilities, utilizing clean energy natural gas for boiler operations[96]. - The company reported a total of 1.25429 tons of COD emissions for the first half of the year, with no exceedance of discharge standards[95]. - The company is committed to environmental responsibility, as evidenced by its adherence to pollution control measures and standards[97]. Legal and Compliance Issues - The company is involved in multiple legal disputes, including a significant case with Chongqing Deep Hong Construction Development Co., Ltd.[120]. - Hainan Haiyao has received a court ruling to pay RMB 10 million as a prepayment for equity transfer along with a penalty of RMB 619,500[121]. - The company has a legal obligation to pay a total of RMB 481,273.1 for attorney fees, insurance, and preservation fees[121]. - The company has not reported any issues or other circumstances regarding the use and disclosure of raised funds[72]. - There were no significant litigation or arbitration matters reported during the period[119]. Future Outlook - The company expects a revenue growth forecast of 15% for the next fiscal year, driven by new product launches and market expansion strategies[194]. - The overall market outlook remains positive, with expectations of continued growth in the pharmaceutical industry driven by increasing healthcare demands[195]. - The company plans to expand its market presence by investing in new product development and enhancing its research capabilities[195]. - The company aims to achieve a revenue growth target of 20% for the next half-year, driven by new product launches and market expansion strategies[198].

海南海药股份有限公司 2022 年第一季度报告全文 证券代码：000566 证券简称：海南海药 公告编号：2022-037 海南海药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 553,628,983.97 | 545,255,859.45 | 1.54% | | 归属于上市公司股东的净利润（元） | -17,663,582.45 | -151,134,42 ...

Financial Performance - The company's operating revenue for 2021 was ¥2,059,062,761.85, representing a decrease of 6.42% compared to ¥2,200,313,977.32 in 2020[19]. - The company has faced a decline in revenue compared to previous years, with 2019 revenue at ¥2,445,289,306.23[19]. - The net profit attributable to shareholders of the listed company for 2021 was -1,555,415,451.91 CNY, a decrease of 168.08% compared to -580,209,133.90 CNY in 2020[20]. - The operating income for 2021 was 2,059,062,761.85 CNY, down from 2,200,313,977.32 CNY in 2020, representing a decline of approximately 6.4%[20]. - The total assets at the end of 2021 were 8,362,720,404.64 CNY, a decrease of 18.64% from 10,279,231,596.61 CNY at the end of 2020[20]. - The net assets attributable to shareholders decreased by 42.01% to 2,149,227,286.82 CNY from 3,706,114,482.42 CNY in 2020[20]. - The company reported a basic and diluted earnings per share of -1.1989 CNY for 2021, compared to -0.4472 CNY in 2020, reflecting a decline of 168.09%[20]. - The revenue from the pharmaceutical segment was ¥1,784,791,606.56, accounting for 86.68% of total revenue, reflecting an 8.41% decrease from the previous year[52]. - The company reported a total revenue of 93,361 million yuan, with a net profit of -277.64 million yuan for the reporting period[86]. Cash Flow and Investments - The net cash flow from operating activities was 108,223,441.12 CNY, a significant improvement of 192.20% compared to -117,375,748.61 CNY in 2020[20]. - The net cash flow from investment activities improved by 217.54%, reaching ¥607,227,292.82 in 2021, compared to a negative cash flow of ¥516,613,507.44 in 2020[71]. - The net increase in cash and cash equivalents was ¥165,968,568.02 in 2021, a significant recovery from a decrease of ¥180,883,441.49 in 2020, marking a growth of 191.75%[70]. - The company reported a total investment income of ¥28,806,715.68, which accounted for -1.85% of total profit, primarily from the disposal of long-term equity investments[75]. - The company recognized a fair value loss of ¥190,937,542.30, which represented 12.27% of total profit, due to changes in the fair value of financial assets[75]. Research and Development - The company plans to enhance its core competitiveness by focusing on the pharmaceutical sector and improving its production processes and R&D capabilities[30]. - The company aims to accelerate the clinical research of two new Class 1 drugs, Fluorofenone capsules and Painjabin tablets, as part of its R&D strategy[30]. - The company is advancing the development of innovative drugs and generic drugs, maintaining a strong investment in R&D[31]. - The R&D strategy focuses on four key areas: chemical drugs, biological drugs, traditional Chinese medicine, and medical devices, with multiple research centers established[40]. - The company's R&D investment decreased by 36.73% to ¥151,138,214.28 from ¥238,874,718.46, focusing on improving the efficiency of funding usage[49]. - Research and development expenses increased by 55.55% to approximately ¥196.69 million, driven by new strategic initiatives and clinical research investments[65]. Production and Operations - The company has completed Phase I clinical trials for the new drug project targeting liver fibrosis and has initiated Phase II trials with approximately 40 clinical centers approved[31]. - The company has signed contract processing agreements with 5 enterprises to enhance production line utilization and has resumed production of Xiao Chai Hu granules[32]. - The production strategy is based on sales-driven production, with strict quality control procedures in compliance with GMP standards[39]. - The company has established six new workshops in compliance with CGMP and GMP standards, enhancing production quality management capabilities[47]. - The company focuses on high-value generic drugs and specialty medications, with a well-established industrial chain across three major bases[32]. Market and Sales - The company exports raw materials and intermediates to over 30 countries across three continents, enhancing its market reputation[39]. - The sales volume of pharmaceutical products decreased by 3.81% to approximately 138 million units, while production volume dropped by 24.89% to approximately 126 million units[55]. - The revenue from international markets increased by 164.30%, reaching ¥74,528,506.18, compared to ¥28,198,270.61 in the previous year[52]. - The company is actively expanding its market presence through online and offline promotional activities, enhancing brand visibility[40]. - The company plans to enhance its quality management system to create a competitive advantage and ensure quality improvement[115]. Corporate Governance - The company has established an independent financial department with a complete accounting and financial management system, and operates its own bank accounts[129]. - The company conducted six shareholder meetings during the reporting period, ensuring compliance with governance regulations and protecting minority shareholder interests[122]. - The company has committed to resolving any potential industry competition issues with its subsidiaries within five years following the completion of a recent acquisition[131]. - The company emphasizes the importance of compliance and risk management in its operations, as highlighted by the new supervisory board members' backgrounds[144][145]. - The company has implemented a transparent performance evaluation and incentive mechanism for its board and management personnel[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions monitored and reported[175]. - The total emissions of COD were 0.92 tons, well below the annual limit of 3.27 tons[175]. - The company has implemented a comprehensive air pollution control system, including a RCO incineration unit with a capacity of 20,000 Nm³/h[178]. - The company’s wastewater treatment facilities have been upgraded to meet the new environmental requirements, ensuring all treated wastewater meets the first-level discharge standards[177]. - The company has successfully passed the environmental compliance inspections for multiple projects, including the production lines for various antibiotics[180]. Legal and Compliance Issues - The company incurred a litigation amount of 722.5 million yuan related to a contract dispute, with a judgment requiring the defendant to return the amount[197]. - The company has reported a total of RMB 1.83 million in a settlement reached with Jiangsu Hanku Biological Co., Ltd. for various fees[199]. - The company is pursuing claims against multiple parties for various amounts, including a claim of RMB 2.25 million against a technology company[199]. - The company has been involved in a bankruptcy case with a total claim amount of RMB 8.5 million against Chongqing Deep Hong Construction Development Co., Ltd.[198]. - The company has not faced any penalties from securities regulatory authorities for its directors or senior management in the past three years[155].

Financial Performance - The company's revenue for Q3 2021 was ¥469,377,367.76, a decrease of 20.16% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥120,019,779.30, representing a decline of 252.77% year-on-year[3]. - The basic earnings per share for the period was -¥0.0925, down 262.75% from the previous year[3]. - The company's net profit for the third quarter decreased by 112.48% year-on-year, resulting in an undistributed profit of -939,146,861.63 CNY[8]. - Net profit for the current period is approximately -¥523.44 million, compared to -¥5.76 million in the previous period, indicating a significant decline[21]. - Basic and diluted earnings per share for the current period are both -¥0.3832, compared to ¥0.0144 in the previous period[22]. - The company reported a total comprehensive loss of approximately -¥524.20 million, compared to a gain of ¥1.12 million in the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥9,194,556,251.29, a decrease of 10.55% from the end of the previous year[3]. - The total number of ordinary shareholders at the end of the reporting period was 56,284, with no preferred shareholders[9]. - The company's total current assets decreased to CNY 4,219,280,354.29 from CNY 5,211,898,578.11, reflecting a reduction of about 19.1%[16]. - The total liabilities decreased to CNY 5,710,596,090.83 from CNY 6,307,612,628.58, which is a reduction of about 9.5%[17]. - The total equity attributable to the parent company decreased to CNY 3,277,596,571.24 from CNY 3,706,114,482.42, reflecting a decline of about 11.6%[18]. - Total liabilities amounted to CNY 6,307,612,628.58, with non-current liabilities at CNY 1,290,414,219.49[30]. - Total equity attributable to shareholders reached CNY 3,706,114,482.42, while total equity was CNY 3,971,618,968.03[30]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥34,263,405.38, an increase of 129.25%[3]. - Cash flow from operating activities increased by 129.25% to 34,263,405.38 CNY, attributed to higher cash receipts from sales and reduced expenses[8]. - The net cash flow from operating activities for Q3 2021 was ¥34,263,405.38, a significant improvement from a net outflow of ¥117,122,155.26 in Q3 2020[25]. - The company's cash flow from financing activities showed a net outflow of -591,585,653.87 CNY, an increase of 1108.48% due to higher bank loan repayments[8]. - The net cash flow from financing activities was negative at -¥591,585,653.87, contrasting with a positive net flow of ¥58,661,001.15 in Q3 2020[25]. Investments and Expenditures - The company reported a significant increase in research and development expenditures, impacting cash reserves[7]. - Research and development expenses increased to approximately ¥51.04 million, up from ¥45.33 million in the previous period[19]. - Investment activities generated a net cash flow of 374,179,447.67 CNY, a significant increase of 2325.32% due to the recovery of previous term deposits[8]. - Investment losses amounted to approximately -¥401.63 thousand, a significant drop from a gain of ¥13.70 million in the previous period[19]. Shareholder Information - The largest shareholder, Hainan Huadong Industrial Co., Ltd., holds 22.89% of the shares, amounting to 296,989,889 shares[10]. - The company provided financial assistance of up to CNY 20 million to its associate company, Chongqing Yade Technology Co., Ltd., with an annual interest rate of 8%[12]. - The company has guaranteed a balance of CNY 149,750,000 for Yade Technology, with overdue guarantees amounting to CNY 139,850,000[12]. Other Financial Metrics - The weighted average return on equity was -2.96%, reflecting a decline of 2.20% compared to the previous year[3]. - The company reported a total non-operating loss of -¥12,850,773.71 for the period[5]. - Other income decreased by 30.47% to 34,571,786.38 CNY, mainly due to reduced government subsidies related to daily operations[8]. - The company reported a 3708.73% decline in fair value changes, resulting in a loss of -260,349,554.11 CNY due to stock value adjustments[8]. - The company's inventory stock was completely written off, resulting in a 100% decrease in treasury shares[8]. Adjustments and Compliance - The company adjusted its financial statements in accordance with the new leasing standards effective from 2021[26]. - The third quarter report was not audited, indicating potential implications for financial reliability[31].